Erik A.
- Country
- Sweden
- Department
- Avdelningen för hematologi
Research Overview
- Evaluation of Bomedemstat Versus Best Available Therapy in Essential Thrombocythemia Patients with Hydroxyurea Intolerance or Inadequate Response
- ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
- Phase 3 Randomized Study of Bomedemstat vs. Hydroxycarbamide in Cytoreductive Therapy-Naïve Essential Thrombocythemia Patients
Data & Insights
Has run more than one trial at 42 of 137 partner sites.
Specializations
Chronic Myeloid Leukemia
The investigator specializes in developing innovative treatment approaches for chronic myeloid leukemia, with particular focus on combination therapies involving ropeginterferon and bosutinib. Their research explores optimization of treatment protocols aimed at achieving deep molecular responses.
- Treatment-free remission strategies
- Long-acting interferons
- Targeted therapy combinations
Essential Thrombocythemia
The investigator conducts comprehensive research in essential thrombocythemia treatment, particularly focusing on novel therapeutic agents like bomedemstat. Their work includes comparative studies against conventional treatments such as hydroxyurea for patients with varying treatment responses.
- Treatment-resistant cases
- Alternative therapy development
- Durable clinical response assessment
Acute Lymphoblastic Leukemia
The investigator focuses on advancing treatment protocols for acute lymphoblastic leukemia across diverse age groups, from infants to young adults. Their research encompasses novel immunotherapy approaches and interventional studies aimed at improving survival outcomes.
- Age-specific treatment protocols
- Survival improvement strategies
- Quality of survival assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.